There is also considerable potential for other industries using hemp in the manner that the automobile industry has demonstrated is feasible. Of course, all other types of transportation vehicles from bicycles to airplanes might make use of such technology. Natural fibers have considerable advantages for use in conveyance (Karus et al. 2000): low density and weight reduction, favorable mechanical, acoustical, and processing properties (including low wear on tools), no splintering in accidents, occupational health benefits (compared to glass fibers), no off-gassing of toxic compounds, and price advantages. Additional types of composite using hemp in combination with other natural fibers, post-industrial plastics or other types of resins, are being used to produce non-woven matting for padding, sound insulation, and other applications.
CBC is another lesser-known yet still crucial cannabinoid in marijuana, especially from a therapeutic perspective. While bereft of the psychoactive quality of THC (and to a lesser extent THCV), CBC is gaining popularity as an anxiety reducer. While research on cannabichromene lags behind others, there’s good reason to continue looking into its potential as a medicine.
At least 50% of patients who receive moderately emetogenic chemotherapy may experience delayed chemotherapy-induced N/V. Although selective neurokinin 1 antagonists that inhibit substance P have been approved for delayed N/V, a study was conducted before their availability to assess dronabinol, ondansetron, or their combination in preventing delayed-onset chemotherapy-induced N/V.[34] Ondansetron, a serotonin 5-hydroxytryptamine 3 (5-HT3) receptor antagonist, is one of the mainstay agents in the current antiemetic armamentarium. In this trial, the primary objective was to assess the response 2 to 5 days after moderately to severely emetogenic chemotherapy. Sixty-one patients were analyzed for efficacy. The total response–a composite endpoint–including nausea intensity, vomiting/retching, and use of rescue medications, was similar with dronabinol (54%), ondansetron (58%), and combination therapy (47%) when compared with placebo (20%). Nausea absence was greater in the active treatment groups (dronabinol 71%, ondansetron 64%, combination therapy 53%) when compared with placebo (15%; P < .05 vs. placebo for all). Occurrence rates for nausea intensity and vomiting/retching episodes were the lowest in patients treated with dronabinol, suggesting that dronabinol compares favorably with ondansetron in this situation where a substance P inhibitor would currently be the drug of choice.
^ Jump up to: a b c d Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (December 2012). "Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences (Review). 367 (1607): 3364–78. doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
Royal Queen Seeds CBD Oil offers a convenient, discreet and quick way to dose yourself with a bit of CBD, no matter your situation or where you are. All of our CBD oil is created using organically grown hemp sourced from right here in Europe, extracted using the latest CO² techniques. It means our oil is 100% natural, offering pure and strong CBD. All you need to do as drop you dose under your tongue or in your food, and away you go!
There have been ten clinical trials on the use of inhaled Cannabis in cancer patients that can be divided into two groups. In one group, four small studies assessed antiemetic activity but each explored a different patient population and chemotherapy regimen. One study demonstrated no effect, the second study showed a positive effect versus placebo, the report of the third study did not provide enough information to characterize the overall outcome as positive or neutral. Consequently, there are insufficient data to provide an overall level of evidence assessment for the use of Cannabis for chemotherapy-induced N/V. Apparently, there are no published controlled clinical trials on the use of inhaled Cannabis for other cancer-related or cancer treatment–related symptoms.
On the other hand, marijuana-derived CBD and anything else derived from a cannabis plant was still classified by the DEA as a Schedule I drug (defined as a drug with "no currently accepted medical use and a high potential for abuse") until October 2018. In 2016, the DEA stated that all extracts containing more than one cannabinoid would remain classified as Schedule I. However, the approval of Epidiolex had an influence in changing this, and prescription CBD drugs with a THC content of below 0.1% have now been reclassified as Schedule 5, the lowest rating.
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.

Hemp Products

×